Preimplantation Genetics Diagnosis Companies and Future Market Positioning

Which are the Top Companies in the Market?

• IGENOMIX
• Natera/PGT solutions
• CooperSurgical/Reprogenetics
• BGI/BGI Genomics
• Invitae
• Genea Biomedx
• Illumina
• Thermo Fisher Scientific
• Agilent Technologies
• PerkinElmer
• MGI/Complete Genomics
• Sage Labs/CooperGenomics
• Academic/clinic networks offering high-volume in-house PGT
• Specialized niche providers of niPGT and embryo analytics
• Consumables & biopsy instrument suppliers

Market Forecast

The global preimplantation genetics diagnosis (PGD) market size is calculated at US$ 67.79 Million in 2024, grew to US$ 73.1 million in 2025, and is projected to reach around US$ 144.19 million by 2034. The market is expanding at a CAGR of 7.84% between 2025 and 2034.

Trends in North America

U.S. Market Trends

A large volume of IVF procedures is conducted in the U.S., which is increasing the use and adoption of PGD. They are also increasing the use of non-invasive embryo testing and digital PCR platforms. The companies are also increasing their innovations. Moreover, the growing awareness is also increasing their adoption rates.

Canada Market Trends

There is a rise in the adoption of PGD in Canada due to growing IVF procedures. They are also being supported by the government. At the same time, funding is also provided to promote their development and adoption. Additionally, the fertility clinics are also increasingly utilizing such advanced platforms.

Market Value Chain Analysis

R&D

To enhance the diagnostic accuracy and clinical outcomes, the R&D of preimplantation genetics diagnosis (PGD) is focusing on developing high-resolution genetic analysis techniques, such as less invasive embryo biopsy methods and next-generation sequencing.

Key Players: Thermo Fisher Scientific, Illumina, Revvity, Agilent Technologies, The Cooper Companies Inc.

Clinical Trials and Regulatory Approvals

The clinical trials of preimplantation genetics diagnosis (PGD) include the development of best practices and clinical utility, while the regulatory approval focuses on its quality assurance.

Key Players: Thermo Fisher Scientific, Illumina, Agilent Technologies, Roche, PerkinElmer.

Packaging and Serialization

The prevention of mixups and preservation of the samples is included in the packaging and serialization of the preimplantation genetics diagnosis (PGD).

Key Players: Abdos Labtech Private Limited, Thermo Fisher Scientific, Cole-Parmer, World Courier.

Distribution to Hospitals

The preimplantation genetics diagnosis (PGD) distribution to hospitals includes the transportation of embryonic cells from fertility clinics to genetic testing facilities.

Key Players: Natera, MedGenome, IGENOMIX, World Courier.

Patient Support and Services

The psychological and specialized genetic counselling is offered to the couples to navigate ethical dilemmas, understand complex results, and cope with the significant emotional stress of testing and IVF procedures, in the patient support and services of the preimplantation genetic diagnosis (PGD).

Key Players: NovaIVF Fertility, Apollo Fertility, Cloudnine Fertility, Birla Fertility and IVF, Indira IVF, Carrot Fertility, FertileThoughts.

Latest Announcements by Industry Leaders

In June 2025, the Founder and CEO of Juniper Genomics, Jeremy Grushcow, stated that there is a growth in the questions arising from patients as the IVF journey can be emotionally exhausting, expensive, and low success rate for embryo testing. Most failures are because of the embryos that are not viable. Therefore, they focus on providing the families the compassionate, clear, and responsible care at every step by combining cutting-edge science with rigorous ethical standards by collaborating with IVF clinicians.

What are the Recent Developments in the Market?

• In May 2025, the PGT-A test (Preimplementation Genetic Test for Aneuploidy) was launched by Centogene. They further highlighted that it improves the diagnostic accuracy, traceability, and sensitivity as it consists of around 1,000,000 sequences of the genetic database along with proprietary technologies.
• In April 2025, Non-Invasive Preimplantation Genetic Testing (niPGT) was launched by Orchid Fertility Dubai. With the use of this platform, the stress on embryos will be reduced and enhance the successful pregnancies, revolutionizing the IVF experience.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com